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1.91; p=0.04).
Conclusion: Depression is associated with all-cause mortality and cardiovascular death
or hospitalization following acute MI complicated by heart failure. Studies are warranted
to evaluate whether a depression intervention can improve survival and/or reduce hospi-
talization for these patients.
1069-112 Mortality of Heart Failure Patients From the General 
Population: Effects of the Therapeutic Regimen
Mauro Di Bari, Giorgia Valpiani, Mirko Di Martino, Pierangelo Geppetti, Giulio Masotti, 
Ezio Degli Esposti, University of Florence, Florence, Italy, CliCon Srl Health, Economics 
and Outcomes Research, Ravenna, Italy
BACKGROUND
Randomized clinical trial (RCT) have shown that ACE-inhibitors (ACE-I) and β-blockers
(βB) improve survival in patients with heart failure (HF) with additive effect. Whether
these therapeutic benefits are maintained in HF patients of the “real word” is debated.
This study compared survival of HF patients from the general population as a function of
cardiovascular (CV) drug use.
METHODS
All hospital admissions, drug prescriptions (National Health Service Drug Prescription
Database), and mortality data of the entire population (approximately 360,000) residing
in the health district of Ravenna, Italy have been recorded since 1996. Patients dis-
charged from hospital with a first diagnosis of HF (ICD 9 code 428) from 01.01.1997 to
12.31.1999 were selected from this database and followed up for one year. Patients were
grouped into 5 cohorts according to drug prescription during the follow-up: diuretics (D)
alone, ACE-I alone, D+ACE-I, D+ACE-I+βB, and other drugs. Mortality rates were com-
puted using a person-years denominator. Cox’s model was used to compute mortality
hazard ratio (HR) and 95% confidence interval (95% CI), adjusting for age, sex, history
of: diabetes, hypertension, heart disease and previous CV events (myocardial infarction,
coronary artery disease, stroke, and transient ischemic attack).
RESULTS
2,441 HF patients (mean age 78 ± 10 years; females 53.7%) were included. Of them,
20.2% were on D, 7.2% on ACE-I, 56.2% on D+ACE-I, 5.4% on D+ACE-I+βB, and 11.0%
on other drugs. Crude cumulative mortality was 36.8%, 26.7%, 20.8%, 3.9% and 34.1
respectively (p<0.001). Compared to patients receiving D+ACE-I+βB, the risk of death
increased significantly in those on other regimens, with adjusted HRs (95% CIs) of 3.9
(1.6-9.4), 5.5 (2.2-14.0), 6.3 (2.6-15.6), 6.5 (2.6-16.1) in those on D+ACE-I, ACE-I, D or
other drugs, respectively.
CONCLUSION
In this large cohort of HF patients from the general population, a therapeutic regimen
based on the association D+ACE–I+βB was associated with the lowest mortality. Survival
decreased progressively in participants on D+ACE-I, ACE-I, D, and other drugs. These
results from a non-experimental setting strongly support those obtained from RCT.
1069-113 Cause of Death Across Full Spectrum of Ventricular 
Function in Patients With Heart Failure: The CHARM 
Study
Scott Solomon, Bertil Olofsson, Peter Finn, Hicham Skali, Leonardo Zornoff, Satish 
Kenchaiah, Nagesh Anavekar, Jan Ostergren, Eric Michelson, Uche Sampson, Pratima 
Anavekar, Salim Yusuf, John McMurray, Chris Granger, Marc Pfeffer, Brigham and 
Women's Hospital, Boston, MA
Background: While the incidence and causes of death in heart failure (HF) patients with
reduced left ventricular (LV) systolic function have been previously reported, these have
not been described in patients with preserved systolic function. Methods: The Cande-
sartan in Heart Failure (CHARM) trial enrolled 7601 patients with symptomatic heart fail-
ure, and EF ranging from 5% to 91%. Cause of death was classified by an independent
review committee. The annualized incidence of death was calculated in each quintile
(median follow-up 38 mos). Results: All-cause and CV death declined with each increas-
ing quintile of ejection fraction, whereas non-CV death was similar across quintiles. The
proportion of non-CV death increased in the highest quintile of EF. Sudden death and
fatal HF accounted for the majority of CV death and the proportion of death attributable to
sudden death or HF decreased with EF. The annual incidence of fatal MI was low (<1% in
all groups). The proportion of deaths attributable to MI or stroke was similar across quin-
tiles. Conclusion: In HF patients with a broad range of ejection fractions, death attrib-
uted to sudden death and HF accounted for the majority of the cardiovascular death,
although in decreasing absolute number and proportion with increasing EF. These find-
ings have important implications for the choice of end-points in trials in patients with heart
failure and preserved LV systolic function. 
1069-114 Impact of Renal Insufficiency and Chronic Diuretic 
Therapy on Outcome and Resource Utilization in 
Patients With Acute Decompensated Heart Failure
Maria Rosa Costanzo, J. Thomas Heywood, Teresa DeMarco, Gregg C. Fonarow, Janet 
S. Wynne, Midwest Heart Specialists; Edward Hospital, Naperville, IL
Background: There is a paucity of information on renal insufficiency (RI) in patients (pts)
with heart failure (HF) due to exclusion of RI pts from HF clinical trials. Methods: Data
from 46,599 hospitalizations (Apr, 2003) for decompensated HF were collected in the
ADHERETM Registry. Of 35,423 pts with Cr < 2.0 mg/dl, 10,648 (30%) did not receive
chronic diuretics (ChD) (A) and 24,775 (70%) did (B). Of 10,317 pts with Cr > 2.0 mg/dl,
2,937 (28%) did not receive ChD (C) and 7,380 (72%) did (D). Resource utilization and
outcomes were compared in the 4 groups (Chi square and ANOVA). Results: There was
a stepwise increase in in-hospital mortality with the lowest rate occurring in A and the
highest in D. In pts with low and high Cr, use of ChD was associated with the highest
mortality rate. A stepwise decrease in the percentage of cases who were completely
asymptomatic at discharge, with the highest percentage in A and the lowest percentage
in D, was observed. Use of ChD was associated with fewer asymptomatic discharges in
pts with low and high Cr, (46% vs. 52% and 39% vs. 45%; both P < 0.0001). There was a
stepwise increase in hospital length of stay (LOS) with the shortest in A and the longest
in D. In pts with low and high Cr ChD were associated with longer LOS (5.5 ± 4.9 vs. 5.8
± 6.1 days, P<0.0001 and 6.1± 5.8 vs. 6.9 ± 6.1 days, P< 0.0001). Conclusions: RI
worsens patient outcomes in terms of resource utilization, symptom status and survival.
ChD were associated with poorer outcomes and greater resource utilization in pts with
and without RI.
1069-115 Prognostic Significance of Deteriorating Renal Function 
in Patients With Decompensated Heart Failure
Doron Aronson, Darlane P. Horton, Andrew J. Burger, Rambam Medical Center, Haifa, 
Israel, Beth Israel Deaconess Medical Center, Boston, MA
Introduction: Renal dysfunction frequently accompanies heart failure progression, and
deterioration of renal function in patients (pts) admitted with decompensated CHF is
common. However, the prognostic significance of worsening renal function in this setting
is not known.
Methods: We studied the relation between deterioration of renal function and 6-month
mortality in 498 pts admitted with decompensated CHF. Deterioration of renal function
was defined as an increase of > 0.5 mg/dL in creatinine level within 14 days from admis-
sion.
Results: At 14-days, 103 pts (21%) had evidence of deteriorating renal function. During
a 6-month follow-up, 112 pts (22%) died. Kaplan-Meier analysis is shown in the Figure. A
Cox proportional-hazards model, adjusted for age, gender, diabetes, etiology of CHF,
baseline creatinine, baseline heart rate, EF, atrial fibrillation, and medications (ACE inhib-
itors, β-blockers, digoxin, or amiodarone use), showed that deteriorating renal function
was a strong independent predictor of 6-month mortality (RR = 2.93, 95% CI 1.81-4.72, p
< 0.0001). Baseline creatinine was also an independent predictor of 6-month mortality
(RR = 1.20 for every 1.0 mg/dL increase, 95% CI 1.06-1.36, p = 0.003), but was not pre-
dictive of deteriorating renal function.
Conclusion: In pts admitted for heart failure decompensation, evidence of deteriorating
renal function is a powerful independent predictor of short-term mortality. 
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1069-116 Prevalence and Importance of Renal Dysfunction in 
Hospitalized Heart Failure Patients
Colin Berry, John McMurray, University of Glasgow, Glasgow, United Kingdom
Background: Renal dysfunction is an adverse prognostic marker in heart failure (HF).
Although serum creatinine concentration is the usual method for assessing renal dys-
function, the accuracy of this test in HF is uncertain. Consequently, the true prevalence of
renal dysfunction in unselected HF patients is unknown.
Methods: Index emergency admissions with HF to one University hospital during the year
2000 were studied. Hematological and biochemical (from the initial blood samples taken
on the day of admission) data were obtained from hospital electronic records.
Results: 528 consecutive, first-admissions, with HF were included in this study. The
median follow-up was 693 days (range 1 - 978 days). Mean serum creatinine (standard
deviation [SD]) concentration on admission was 1.5(0.9) mg/dL and 51% of patients had
an elevated creatinine (>1.3 mg/dL) concentration. Glomerular filtration rate (GFR) was
calculated using the Modified Diet in Renal Disease equation. Mean GFR was 51(22)
mL/min/1.73m2. Mean GFR of men was greater than that of women (56(23) vs 48(20);
P=0.0001). 436(96%) patients had a reduced GFR (<90 mL/min/1.73m2 ). 66%, 16%,
and 3% had a GFR less than 60, 30 and 15 mL/min/1.73m2, respectively. 199/219 (90%)
of patients with a normal creatinine had a low GFR. On multiple regression analysis, age
(coefficient of variation [95% confidence interval]; -0.6 (-0.7, -0.4); P<0.0001), male sex
(11 (6,16); P<0.0001), ACE inhibitor therapy (6.1(0.9, 11); P=0.02), Hb (1.6(0.4, 2.8) and
plasma CRP (0.6(-0.1,-0.02) were independent predictors of GFR.
On Cox survival analysis, GFR (SD) was an independent predictor of mortality (odds
ratio [95% confidence interval] 0.89 [0.78,1.0]; P<0.08), HF readmission (0.8 [0.6,1.1;
P=0.02] and death or HF readmission (0.8 [0.7,1.0]; P=0.03).
CONCLUSIONS: Measurement of serum creatinine fails to detect impaired renal function
in a high proportion of hospitalized HF patients. Normal renal function on admission is
rare in these patients, and GFR is an independent predictor of long-term outcomes. In
addition to established predictors of renal function, we found that ACE-I therapy and
plasma CRP concentrations are also predictors.
1069-117 Prognostic Impact of Catabolic/Anabolic Imbalance in 
Chronic Heart Failure 
Darlington O. Okonko, Martino Crosato, Wolfram Steinborn, Stephan von Haehling, 
Mariantonietta Cicoira, Wolfram Doehner, Paul R. Kalra, Phillip A. Poole-Wilson, Stefan 
D. Anker, Imperial College, National Heart and Lung, London, United Kingdom, Applied 
Cachexia Research, Charité, Virchow-Klinikum, Berlin, Germany
Background: Chronic heart failure (CHF) is characterised by a catabolic/anabolic imbal-
ance. The cortisol/DHEA ratio (CDR) reflects this disequilibrium. Its prognostic utility is
unknown.
Method & Results: Survival and CDR were analysed in 102 stable male CHF patients
(age 62±11y, NYHA class 2.6±0.7, CDR 50±5, urate 468±136 µmol/L, creatinine 124±43
µmol/L, body mass index 26.1±4.4 kg/m2, left ventricular ejection fraction 26±11 %, peak
oxygen consumption(VO2) 18.1±5.8 mL/kg/min, ventilation/carbon dioxide production
slope (VE/VCO2) 38±13). During follow-up (55±40 months, all survivors:>16 months), 48
patients died (12-month mortality 15%, at 36 months: 38%). In univariant Cox analysis
only CDR, urate, creatinine, NYHA, VE/VCO2, peak VO2, age (all p<0.01) and body
mass index (p=0.03) predicted survival. In bivariant models CDR was universally inde-
pendently predictive of survival. Urate, NYHA, VE/VCO2 and peak VO2 predicted sur-
vival, independently of CDR. In multivariant analysis, CDR(p<0.0001), urate (p=0.008),
NYHA class (p=0.002), VE/VCO2 (p=0.04) but not peak VO2 (p>0.2) were independent
prognosticators. We subdivided patients by CDR quartiles (Q, see figure). Survival at 36
months for patients in Q1, Q2, Q3 and Q4 was 92, 81, 67 and 35% respectively.
Conclusion: Catabolic/anabolic imbalance(quantified by the cortisol/DHEA ratio) inde-
pendently predicts survival in CHF. Therapeutic strategies blunting catabolism and/or
augmenting anabolism may confer prognostic benefits in CHF. 
1069-118 Frequency Distribution of Hospitalized Heart Failure 
Patients: Data From the Adjudication Committee of Val-
HeFT
Peter E. Carson, Ileana L. Pina, Cristina Opasich, Christopher O'Connor, Felix Tristani, 
Lynne Warner Stevenson, Allen Hester, Nancy Feliciano, Nora Aknay, Veteran Affairs 
Medical Center, Washington DC, DC
Background: Categorization of hospitalization data, particularly by adjudication commit-
tees, has been rare in heart failure (HF) trials which have commonly targeted HF
events.In ValHeFT, we examined the adjudicated hospitalization database, 49.7% of
admissions, to categorize non HF hospitalizations.
Methods: The independent endpoints committee (EC) of Val-HeFT adjudicated every
non-elective hospitalization up to and including the first of each primary event. All hospi-
talizations were categorized as HF or non-HF (and cardiovascular (CV) or non-CV). For
CV/non CV, body systems were classified using the MEDDRA dictionary if an EC assign-
ment was not made. Multiple hospitalizations occurred for some patients.
Results: For 5010 patients randomized, 5962 hospitalizations were investigator-
assessed for 2509 patients, and 2962 hospitalizations were EC-adjudicated for 1834
patients. Of the patients with adjudicated hospitalizations, 83.0% (1522) had at least one
hospitalization classified as CV-related, approximately 34% (618) as non-CV, 44.3%
(812) as HF-related, and 71.8% (1316) as non-HF (including CV-related). Among CV rea-
sons other than HF, unstable angina (249, 13.6%) and invasive cardiac procedures (159,
8.7%) were common, while myocardial infarction (MI) (59, 3.2%) and stroke (51, 2.8%)
were not. Leading non-CV causes were infection (197, 10.7%), general disorders (e.g.,
chest pain NEC, malaise) (136, 7.4%), and pulmonary (83, 4.5%). Among the 812
patients with HF hospitalizations, 718 (88.4%) met criteria by IV use or oral medication
addition, 87 (10.7%) with pulmonary edema, and 16 (2.0%) with shock.
Conclusion: Non-HF hospitalizations appear commonly in HF patients. Among non HF
CV admissions, unstable angina and invasive cardiac procedures were common and irre-
versible CV endpoints (MI and stroke) were infrequent. Future HF trials may consider
those proportions of hospitalizations in designing composite endpoints and in further
assessing the importance of non-HF morbidity in the disease.
1069-119 Predictors of Mortality in Patients Hospitalized With 
Worsening Heart Failure: Insights From the ACTIV in 
CHF Trial
Christopher M. O'Connor, Kirkwood F. Adams, Jr., Wendy A. Gattis, Alejandro 
Barbagelata, Uri Elkayam, Frank Mc Grew, Jalal Ghali, Raymond Benza, Marc Klapholz, 
John Ouyang, Cesare Orlandi, Mihai Gheorghiade, Northwestern University Feinberg 
School of Medicine, Chicago, IL
Background: Patients hospitalized for worsening heart failure have a high post-dis-
charge mortality and readmission rate. Limited information, however, exists for risk strati-
fication in this population.
Methods: The Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in
Chronic Heart Failure (ACTIV in CHF) trial randomized 319 patients admitted to the hos-
pital for worsening heart failure to tolvaptan or placebo, in addition to standard therapy.
Cox proportional hazards analysis was used to explore the relation between baseline
characteristics and mortality within 60-day post-discharge, adjusted for treatment. Base-
line variables examined included demographics, history, renal function, and clinical labo-
ratory values. 
Results: The overall unadjusted 60-day mortality was 5.8% and the 60-day mortality/re-
hospitalization rate was 26.7%. The two most important baseline independent predictors
of mortality were elevated BUN (BUN > 29 mg/dL; HR = 5.54, 95% CI 2.17 - 14.17, p <
0.0004) and hyponatremia (serum Na < 136 mEq/L; HR = 3.12, 95% CI 1.47 - 6.61, p <
0.003). Anemia (Hemoglobin < 13 for men and < 12 for women; HR 1.59; 95% CI 0.72 -
3.52, p = 0.26) and low systolic blood pressure (systolic blood pressure < 90 mm Hg; HR
= 1.94, 95% CI 0.49 - 7.68, p = 0.34), trended toward statistical significance.
Conclusions: In patients discharged after hospitalization for worsening heart failure, ele-
vated BUN and hyponatremia are strong predictors of 60-day mortality. Clinical decision-
making processes and further research efforts should target these two factors.
